Quinapyramine Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is an aminoquinaldine-derived trypanocide released as the sulfate salt and the chloride salt. The sulfate is the water-soluble component used for immediate-release solutions, tablets, capsules, granules, and premixes. The chloride is a low-solubility component used for injectable suspensions and depot-type preparations. In products containing both salts, the sulfate fraction supplies early trypanocidal exposure and the chloride fraction provides prolonged release through slow dissolution at the injection site or in the gastrointestinal environment. The two salts are not chemically interchangeable because their solubility, particle-size, sterility, and handling profiles differ.

Where contract manufacturing requires a specific model designation, the sulfate is assigned material code QP-S and the chloride QP-C for batch traceability; a co-milled QP-MX grade may be supplied for dry blends and premixes. These codes are internal traceability models and are not compendial nomenclature. Batches are released after analytical certification and are linked to a retained sample stored under controlled room temperature.

Because no universal pharmacopoeial monograph is adopted in all jurisdictions, release specifications are drawn from compendial general methods and in-house validated methods. Assay is set at 98.0% to 102.0% on the dried basis by stability-indicating HPLC validated according to ICH Q2(R2). Loss on drying is ≤0.5% by Ph. Eur. 2.2.32. Residue on ignition is ≤0.1%. Heavy metals are controlled at ≤20 µg/g by Ph. Eur. 2.4.8 or by elemental impurity analysis under ICH Q3D when the intended dose and animal species require a risk-based limit. Residual solvent limits follow ICH Q3C Option 1. Non-sterile oral and feed powders are tested by Ph. Eur. 2.6.12 and 2.6.13 with total aerobic microbial count ≤10³ CFU/g and total combined yeasts/moulds ≤10² CFU/g. Sterile injection grades are tested for bacterial endotoxins per Ph. Eur. 2.6.14 and sterility per Ph. Eur. 2.6.1.

Identification is confirmed by infrared absorption spectrophotometry against a qualified working standard and by HPLC retention time. The same HPLC procedure quantifies related substances. In-house acceptance criteria for unspecified impurities are ≤0.10% each and total impurities ≤0.50%; published data for the full impurity and degradation profile is limited because a harmonised monograph is not available.

What Distinguishes Quinapyramine Sulfate from the Chloride Salt in a Dosage Form?

Solubility is the primary differentiating property. Quinapyramine sulfate is dissolved in water for injection or purified water to produce clear solutions. Quinapyramine chloride remains largely undissolved and is dispersed as a micronized suspension. Injectable products that combine both salts therefore require two separate manufacturing streams: a sterile solution line for the sulfate and a sterile suspension line for the chloride. The suspension line requires continuous agitation, a wetting vehicle, and particle-size control to prevent sedimentation and needle block.

The chloride particle-size distribution is controlled by laser diffraction under wet dispersion. For injectable suspensions, a common upper limit is Dv90 ≤75 µm, with Dv50 ≤20 µm for acceptable syringeability through a 21 G needle. For oral powders and premixes, the sulfate or co-milled material is commonly controlled at Dv90 ≤250 µm to reduce dusting while preserving blend uniformity. These values are application-specific and must be confirmed for the finished formulation by process-capability and stability studies.

Direct compression of quinapyramine sulfate is often insufficient when the API level is below 10% w/w because segregation occurs in the hopper and the blend may stratify during transfer. Dry granulation by roller compaction is therefore selected for tablet and capsule intermediates. After granulation, bulk density is typically 0.40–0.60 g/cm³, tapped density 0.50–0.70 g/cm³, Carr’s index ≤25, and Hausner ratio ≤1.25 to allow consistent die filling. Capsule formulations are prepared by low-shear tumble blending and encapsulated on a dosator or tamping machine; fill weight is monitored at 15–30 min intervals and controlled within ±3% of target. Dissolution testing uses USP apparatus 2 at 50 rpm in 900 mL of an aqueous medium selected to provide sink conditions.

In feed-mill production, quinapyramine premix is prepared by blending the API with a carrier such as spray-dried lactose, ground maize starch, or calcium carbonate. The API is first mixed at a ratio of 1:10 with carrier for 5 min; the preblend is then transferred into a ribbon blender or double-cone tumbler at fill ratios 0.60–0.70. Blend uniformity is accepted when 10 sampling positions yield an active-content relative standard deviation of ≤5.0%. Segregation is minimised when the API and carrier differ in median particle size by less than 100 µm; otherwise, the API is milled or the carrier is selected to match bulk density.

For dry powder formulations, the API is blended with hydrocolloid binders and disintegrants to make granules for oral drench or in-feed use. The granulation endpoint is reached when wet mass density is between 0.70–0.90 g/cm³; this range indicates sufficient binder distribution without overwetting. Granules are dried in a fluid-bed dryer with inlet air temperature 50–60°C; the drying endpoint is set at loss on drying ≤0.5%. The dry granules are milled and screened to a particle-size distribution of 150–850 µm; fines below 150 µm should be ≤15% w/w to avoid segregation in packaging and feed application.

For solid oral dosage forms, dissolution is evaluated in media representing the gastrointestinal environment of the target species. Buffers at pH 1.2, 4.5, and 6.8 are used to determine whether the sulfate salt releases adequately before gastric emptying in monogastric animals. In ruminant premixes, dissolution testing is less predictive; therefore blend uniformity and particle-size distribution are the primary batch-release controls. Published data for this specific configuration is limited to formulation development reports.

Veterinary API Quality Attributes Across Granules, Premix and Solution Processes

High-shear granulation of quinapyramine sulfate for oral granules requires water addition and impeller torque monitoring. Impeller speed at pilot scale may be 200–500 rpm and chopper speed 1,000–3,000 rpm; these values are equipment-specific. Over-granulation increases mean particle size and reduces tablet tensile strength; under-granulation generates fines that reduce flow and increase dust exposure. Drying is performed at inlet air temperature ≤60°C to limit thermal degradation, and final moisture is controlled to ≤0.5% for dry compression or encapsulation. The dry granules are passed through an oscillating granulator fitted with a 0.8–1.5 mm screen.

Solutions are prepared by adding quinapyramine sulfate to purified water or water for injection under continuous mixing. If forced-degradation studies under ICH Q1B show photodegradation, the solution is filled into amber glass vials or otherwise protected from light. pH is adjusted with dilute hydrochloric acid or sodium hydroxide; the final pH is selected to balance chemical stability with local tolerability. Terminal sterilisation of the sulfate solution may be applied only after confirmation of no hydrolysis or oxidation. If terminal sterilisation is not valid, aseptic filtration through a 0.22 µm membrane is used. The chloride suspension is sterilised by a validated method, usually gamma irradiation or aseptic processing; the selected method must be supported by degradation and physical-stability data.

Manufacture of sterile injections uses contact surfaces of 316L stainless steel and cleaning residue limits based on the next product and the lowest animal dose. Filling lines for suspensions require continuous recirculation and in-line homogenisation to maintain particle-size distribution. A hold time of ≥6 h should be validated for the suspension before filling to ensure no sedimentation or particle aggregation.

Compared with diminazene aceturate, quinapyramine is more frequently formulated as a dual-salt depot injection, whereas diminazene aceturate is commonly administered as a solution. The operational consequence is that quinapyramine chloride requires suspension technology, particle-size analysis, and sterility assurance measures not needed for a simple diminazene solution. Published comparative efficacy and dose-response data vary by host and isolate; published data for this specific formulation configuration is limited.

Compared with isometamidium chloride, quinapyramine is not an automatic replacement because cross-resistance has been reported in Trypanosoma congolense and Trypanosoma evansi field isolates. Ethidium bromide also shares cross-resistance with quinapyramine in some published surveillance reports. The selection of a trypanocide should therefore be based on regional resistance patterns and diagnostic confirmation, not on formulation convenience.

Operational boundaries include the absence of a harmonised maximum residue limit in some jurisdictions; therefore use in food-producing animals must follow national veterinary medicines regulations. The chloride salt is poorly soluble and should not be used in intravenous solutions. The sulfate solution should not be mixed with strongly alkaline vehicles unless compatibility studies are performed, because precipitation or degradation may occur. Published data for this specific formulation configuration is limited.